A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit/hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 5, 2010, Pages 365-375

  Findling, Robert L ^a   Katic, Alain ^b   Rubin, Richard ^c   Moon, Eliot ^d   Civil, Richard ^e   Li, Yunfeng ^e,f  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b Claghorn Lesem Research Clinic Ltd   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d Elite Clinical Trials Inc   (United States)

^e SHIRE   (United States)

^f Cereta Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE;

ADOLESCENT; APPLICATION SITE BURNING; ARTICLE; ATTENTION DEFICIT DISORDER; AUDITORY HALLUCINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TRANSDERMAL PATCH; UPPER RESPIRATORY TRACT INFECTION; VISUAL HALLUCINATION;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; APPETITE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 77958543148     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.0122     Document Type: Article

References (38)

1. Adler LA, Sutton VK, Moore RJ, Dietrich AP, Reimherr FW, Sangal RB, Saylor KE, Secnik K, Kelsey DK, Allen AJ: Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol 26:648-652, 2006.
2. Adler LD, Nierenberg AA: Review of medication adherence in children and adults with ADHD. Postgrad Med 122:184-191, 2010.
3. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th ed., Text Revision. Washington (DC): American Psychiatric Association, 2000.
4. Bloom B, Dey AN, Freeman G: Summary health statistics for US children: National Health Interview Survey, 2005. Vital Health Stat 10 231:1-84, 2006.
5. Brinker A, Mosholder A, Schech SD, Burgess M, Avigan M: Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: A cross-sectional study with interference on the likelihood of treatment in adulthood. J Child Adolesc Psycho-pharmacol 17:328-335, 2007.
6. Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS: Trends in medication treatment for ADHD. J Atten Disord 10:335-342, 2007.
7. Centers for Disease Control and Prevention, National Center for Health Statistics. National Health and Nutrition Examination Survey. Clinical growth charts, July, 2009. http://www.cdc.gov/nchs/nhanes/growthcharts/clinical-charts. htm.
8. Conners CK: Conners' Rating Scales-Revised, Technical Manual. New York: Multi-Health Systems, Inc., 1997.
9. Daytrana [package insert]: Wayne (Pennsylvania): Shire US Inc., 2008.
10. DuPaul G, Power T, Anastopoulos A, Reid R: ADHD Rating Scale-IV: Checklists, Norms and Clinical Interpretation. New York: Guilford Press, 1998.
11. European Medicines Agency: ICH Topic E6 (R1). Guideline for good clinical practice: Step 5. Note for guidance on good clinical practice, July, 2002. Accessed at http://www.emea.europa.eu/pdfs/hu-man/ich/013595en.pdf/.
12. Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, Pratt RD: A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry 69:149-159, 2008.
13. Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, Turnbow JM, Civil R: Long-term tolerability of the methylpheni-date transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin Therapeutics 31:1844-1855, 2009.
14. Findling RL, Turnbow J, Burnside J, Melmed R, Civil R, Li Y: A randomized, double-blind, multi-center, parallel-group, placebo-controlled, dose-optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents. CNS spectr 15:419-430, 2010.
15. Global ADHD Working Group: Global consensus of ADHD/HKD. Eur Child Adolesc Psychiatry 14:127-137, 2005.
16. Heal DJ, Pierce DM: Methylphenidate and its isomers: Their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 20:713-738, 2006.
17. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, Gelowitz DL: Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:919-927, 2006. (Pubitemid 44126866)
18. McGough JJ, Biederman J, Wigal SB, Lopez FA, McCracken JT, Spencer T, Zhang Y, Tulloch SJ: Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry 44:530-538, 2005. (Pubitemid 40720952)
19. McGough JJ, Wigal SB, Abikoff H, Turnbow JM, Posner K, Moon E: A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord 9:476-485, 2006.
20. Pastor RN, Reuben CA: Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004-2006. National Center for Health Statistics, Vital Health Stat 10:1-22, 2008.
21. Pelham WE Jr, Manos MJ, Ezzell CE, Tresco KE, Gnagy EM, Hoffman MT, Onyango AN, Fabiano GA, Lopez-Williams A, Wymbs BT, Caserta D, Chronis AM, Burrows-Maclean L, Morse G: A dose-ranging study of methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry 44: 522-529, 2005a.
22. Pelham WE, Burrows-Maclean L, Gnagy EM, Fabiano GA, Coles EK, Tresco KE, Chacko A, Wymbs BT, Wienke AL, Walker KS, Hoffman MT: Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psycho-pharmacol 13:111-126, 2005b. (Pubitemid 40791820)
23. Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M, Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder: The Texas children's medication algorithm projects: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:642-657, 2006.
24. Pliszka SR, for the AACAP Work Group on Quality Issues: Practice parameters for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:894-921, 2007.
25. Polanczyk G, de Lima MS, Horta BH, Biederman J, Rohde LA: The worldwide prevalence of ADHD: A systematic review and meta regression analysis. Am J Psychiatry 164:942-949, 2007.
26. Rentz AM, Matza LS, Secnik K, Swensen A, Revicki DA: Psychometric validation of the child health questionnaire in a sample of children and adolescents with attention-deficit/hyperactivity disorder. Qual Life Res 14:719-734, 2005.
27. Shire Pharmaceuticals, Inc.: Wayne (Pennsylvania): Shire US Inc., website. Accessed at http://www.daytrana.com/.
28. Spencer TJ, Biederman J, Wilens TE: Efficacy and tolerability of long-term, open-label, mixed amphetamine salts extended release in adolescents with ADHD. CNS Spectrums 10:14-21, 2005. (Pubitemid 41513194)
29. Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R: Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: A 4-week, randomized, doubleblind, placebo-controlled, parallel-group study. J Clin Ther 28:266-279, 2006.
30. Steinhoff KW: Special issues in the diagnosis and treatment of ADHD in adolescents. Postgrad Med 120:60-69, 2008.
31. Theunissen NCM, Vogels TGC, Koopman HM, Verrips GH, Zwin-derman KA, Verloove-Vanhorick SP, Wit JM: The proxy problem: Child report versus parent report in health-related quality of life research. Qual Life Res 7:387-397, 1998.
32. Topolski TD, Edwards TC, Patrick DL: 2002 User's Manual and Interpretation Guide for the Youth Quality of Life (YQOL) Instruments. Seattle (Washington): University of Washington, Department of Health Services, 2002.
33. U.S. Department of Health, Education, and Welfare: Clinical global impressions. In: ECDEU Assessments Manual for Psychopharmacology, Revised. Rockville (Maryland): National Institute of Mental Health, pp 217-222, Pub. No. (ADM) 76-338, 1976.
34. Varni JW, Burwinkle TM: The PedsQL as a patient-reported outcome in children and adolescents with attention-deficit/hyperactivity disorder: A population-based study. Health Qual Life Outcomes 4:26, 2006.
35. Vierhile A, Robb A, Ryan-Krause P: Attention-deficit/hyperactivity disorder in children and adolescents: Closing diagnostic, communication, and treatment gaps. J Pediatr Health Care 23:S5-S22, 2009.
36. Wilens TE, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, August G, Greenhill L, McBurnett K, Palumbo D, Swanson J, Wolraich M: ADHD treatment with once-daily OROS methylphe-nidate: Interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 42:424-433, 2003.
37. Wilens TW, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM: Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 160:82-90, 2006.
38. Wilens TE, Boellner SW, López FA, Turnbow JM, Wigal SB, Childress AC, Abikoff HB, Manos MJ: Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 47:700-708, 2008.